Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.00 +1.7%	$3.18	$2.07 ▼ $4.20	$96.63M	0.43	104,513 shs	24,865 shs
CRDL Cardiol Therapeutics	$1.10 -2.2%	$1.30	$0.77 ▼ $2.63	$91.66M	1.05	387,025 shs	837,781 shs
ENLV Enlivex Therapeutics	$1.04 -5.0%	$1.26	$0.81 ▼ $2.10	$24.48M	0.8	261,076 shs	265,988 shs
SRZN Surrozen	$11.56 +1.4%	$9.56	$5.90 ▼ $18.17	$99.07M	0.6	19,496 shs	19,512 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-1.34%	+1.03%	-10.33%	+13.03%	-11.94%
CRDL Cardiol Therapeutics	-2.61%	-3.45%	-26.80%	-10.40%	-41.97%
ENLV Enlivex Therapeutics	+0.93%	-0.91%	-13.49%	+15.22%	-12.80%
SRZN Surrozen	+2.70%	-0.87%	+22.45%	+34.43%	+21.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.4324 of 5 stars	3.5	3.0	1.1	3.3	0.0
CRDL Cardiol Therapeutics	2.3423 of 5 stars	3.7	2.0	3.4	0.0	0.6
ENLV Enlivex Therapeutics	3.2245 of 5 stars	3.5	5.0	3.1	0.8	0.6
SRZN Surrozen	2.789 of 5 stars	3.5	2.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.00	Buy	$9.00	203.03% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	617.49% Upside
ENLV Enlivex Therapeutics	3.00	Buy	$10.00	838.97% Upside
SRZN Surrozen	3.00	Buy	$38.50	247.47% Upside

Current Analyst Ratings Breakdown

Latest ENLV, ANIX, SRZN, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/5/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	455.54	N/A	N/A	$0.59 per share	5.03
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
SRZN Surrozen	$10.65M	8.92	N/A	N/A	$5.50 per share	2.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-232.26%	-158.19%	11/13/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)

Latest ENLV, ANIX, SRZN, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	Q3 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
CRDL Cardiol Therapeutics	0.01	2.46	2.46
ENLV Enlivex Therapeutics	N/A	7.20	7.20
SRZN Surrozen	N/A	16.41	16.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
CRDL Cardiol Therapeutics	12.49%
ENLV Enlivex Therapeutics	1.02%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
CRDL Cardiol Therapeutics	5.25%
ENLV Enlivex Therapeutics	12.28%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
SRZN Surrozen	80	8.57 million	4.70 million	Not Optionable

ENLV, ANIX, SRZN, and CRDL Headlines

Recent News About These Companies

Stonepine Capital Management LLC Boosts Stake in Surrozen, Inc. $SRZN

August 26 at 7:38 AM | marketbeat.com

HC Wainwright Issues Positive Forecast for Surrozen Earnings

August 16, 2025 | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Earnings Results

August 11, 2025 | marketbeat.com

Vivo Capital LLC Takes Position in Surrozen, Inc. (NASDAQ:SRZN)

August 9, 2025 | marketbeat.com

Surrozen (NASDAQ:SRZN) Stock Price Down 12.8% - Should You Sell?

August 9, 2025 | marketbeat.com

Surrozen’s Q2 2025: Progress in Eye Disease Therapies

August 8, 2025 | tipranks.com

Surrozen Reports Q2 Profit on Gains

August 8, 2025 | fool.com

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

August 8, 2025 | globenewswire.com

Surrozen to Present at Upcoming Healthcare Investor Conference

August 6, 2025 | globenewswire.com

Surrozen (SRZN) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth

July 1, 2025 | finance.yahoo.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENLV, ANIX, SRZN, and CRDL Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.00 +0.05 (+1.69%)

Closing price 03:58 PM Eastern

Extended Trading

$3.00 0.00 (0.00%)

As of 04:04 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Cardiol Therapeutics NASDAQ:CRDL

$1.10 -0.03 (-2.23%)

Closing price 03:59 PM Eastern

Extended Trading

$1.10 0.00 (0.00%)

As of 04:04 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Enlivex Therapeutics NASDAQ:ENLV

$1.03 -0.06 (-5.05%)

Closing price 03:58 PM Eastern

Extended Trading

$1.05 +0.02 (+1.55%)

As of 04:04 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Surrozen NASDAQ:SRZN

$11.56 +0.16 (+1.40%)

Closing price 03:58 PM Eastern

Extended Trading

$11.56 0.00 (0.00%)

As of 04:04 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time